<DOC>
	<DOCNO>NCT02283372</DOCNO>
	<brief_summary>A phase I study evaluate safety gemcitabine nab-paclitaxel concurrent IMRT locally advance borderline resectable pancreatic cancer . The goal study evaluate chemotherapy regimen provide superior systemic efficacy may safely deliver enhance efficacy tumor direct radiation therapy .</brief_summary>
	<brief_title>Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT Patients With Locally Advanced Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically cytologically confirm locally advanced adenocarcinoma pancreas consider unresectable borderline resectable base institutional standardized criterion unresectability medical inoperability . Patients without regional adenopathy eligible . Prior systemic chemotherapy allow . It anticipate suggested patient enrol study receive minimum approximately 2 month systemic therapy accord routine institutional practice . The patient must also felt treat medical oncologist radiation oncologist candidate treatment gemcitabine/nabpaclitaxel chemoradiotherapy . At least 18 year age . ECOG performance status ≤ 1 Normal bone marrow organ function define : Absolute neutrophil count ≥ 1,000/mcl Platelets ≥ 100,000/mcl Hemoglobin ≥ 9.0 g/dL Total bilirubin ≤ 1.5 x ULN AST ( SGOT ) /ALT ( SGPT ) ≤ 1.5 x IULN Serum creatinine ≤ 1.5 mg/dL calculate CrCL &gt; 60mL/min use Cockcroft Gault formula Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . Ability understand willingness sign IRB approve write informed consent document ( legally authorize representative , applicable ) . Distant metastatic disease , include know brain metastasis . History prior malignancy acceptable , prior radiotherapy region study cancer would result overlap radiation therapy field allow . Currently receive investigational agent . Major surgery within 4 week prior first study drug administration . A history allergic reaction attribute compound similar chemical biologic composition gemcitabine nabpaclitaxel agent use study . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Pregnant and/or breastfeeding . Patient must negative pregnancy test within 14 day study entry . Known HIVpositivity combination antiretroviral therapy potential pharmacokinetic interaction gemcitabine nabpaclitaxel . In addition , patient increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertake patient receive combination antiretroviral therapy indicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>